Table 1.

Function Improvement in Cardiac Function as Seen by Transthoracic Echo (TTE) and Cardiac Magnetic Resonance Imaging (CMR)

Echo, Day 28CMR, Day 28
LVEDD, mmLVESD, mmFS, %LVEDV, μLLVESV, μLEF, %
Sham6.5±0.22.4±0.163±2359±31103±1372±2
MI7.0±0.55.4±0.522±3464±31304±1334±3
MI + Gel6.7±0.35.0±0.325±3535±41354±4635±3
MI + Gel + Empty Cap6.9±0.25.4±0.421±3
MI + Gel + hMSC7.4±0.25.7±0.223±2435±57267±4039±2
MI + Gel + encap hMSC7.0±0.34.0±0.4*44±4*368±15160±11*56±1*
  • Animals treated with encapsulated human mesenchymal stem cells (hMSCs) had preserved end systolic diameter and fractional shortening by TTE. End diastolic diameter was unchanged. Similar results were found by MRI with decreased end systolic volume and improved EF in animals treated with encapsulated hMSCs at 28 days. EF indicates ejection fraction; FS, fractional shortening; LVEDD, left ventricular end diastolic dimension; LVEDV, left ventricular end diastolic volume; LVESD, left ventricular end systolic dimension; LVESV, left ventricular end systolic volume; MI, myocardial infarction.

  • * P<0.05 using Dunnett's test of multiple comparisons.